Community Acquired Pneumonia (CAP) Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Community Acquired Pneumonia (CAP) Market
Community Acquired Pneumonia (CAP) Market: By Testing & Diagnosis (Chest X-ray/radiography, Sputum Gram stain and/or culture, Blood Cultures), By Therapies & Drugs, By Patient Age group & By Geography - Forecast(2018 - 2023)
Report Code : HCR 0128
Updated Date: 25 October, 2018  

1. Community Acquired Pneumonia (CAP) Market - Overview
1.1. Definitions and Scope
2. Community Acquired Pneumonia (CAP) Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography
3. Community Acquired Pneumonia (CAP) Market 
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis 
4. Community Acquired Pneumonia (CAP) Market – Startup companies Scenario
4.1. Top 10 startup company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Market Shares
4.1.4. Market Size and Application Analysis
4.1.5. Venture Capital and Funding Scenario
5. Community Acquired Pneumonia (CAP) Market – Industry Market Entry Scenario
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing business index
5.3. Case studies of successful ventures
5.4. Customer Analysis – Top 10 companies
6. Community Acquired Pneumonia (CAP) Market Forces
6.1. Drivers
6.2. Constraints
6.3. Challenges
6.4. Porters five force model
6.4.1. Bargaining power of suppliers
6.4.2. Bargaining powers of customers
6.4.3. Threat of new entrants
6.4.4. Rivalry among existing players
6.4.5. Threat of substitutes 
7. Community Acquired Pneumonia (CAP) Market - Strategic analysis
7.1. Value chain analysis
7.2. Opportunities analysis
7.3. Product life cycle
7.4. Suppliers and distributors Market Share
8. Community Acquired Pneumonia (CAP) Market – By Testing & Diagnosis (Market Size -$Million / $Billion)
8.1. Market Size and Market Share Analysis 
8.2. Application Revenue and Trend Research
8.3. Product Segment Analysis
8.3.1. Chest X-ray/radiography 
8.3.2. Sputum Gram stain and/or culture
8.3.3. Blood Cultures
8.3.4. Others
8.3.4.1. COMPLETE BLOOD CELL (CBC) COUNT
8.3.4.2. SERUM SODIUM LEVEL
8.3.4.3. SERUM BLOOD UREA NITROGEN (BUN) AND CREATININE LEVELS 
8.3.4.4. SERUM TRANSAMINASE LEVELS 
8.3.4.5. SERUM PHOSPHORUS LEVEL
8.3.4.6. LACTIC ACID LEVEL
8.3.4.7. CREATINE PHOSPHOKINASE (CPK)
8.3.4.8. C-REACTIVE PROTEIN (CRP)
8.3.4.9. LACTATE DEHYDROGENASE (LDH)
8.3.4.10. PROCALCITONIN
8.3.4.11. COLD AGGLUTININ TITERS 
8.3.4.12. URINARY ANTIGEN TESTING
8.3.4.13. SEROLOGIC STUDIES FOR M PNEUMONIAE
8.3.4.14. POLYMERASE CHAIN REACTION (PCR) TESTING
9. Community Acquired Pneumonia (CAP) Market – By Therapies & Drugs (Market Size -$Million / $Billion)
9.1. Antiviral Threapy
9.1.1. RIBAVIRIN 
9.1.2. OSELTAMIVIR
9.1.3. ZANAMIVIR 
9.1.4. ACYCLOVIR 
9.2. Antibiotic Threapy
9.2.1. AMOXICILLIN 
9.2.2. AZITHROMYCIN OR CLARITHROMYCIN
9.2.3. AMPICILLIN 
9.2.4. VANCOMYCIN OR CLINDAMYCIN
9.2.5. CEFTRIAXONE OR CEFOTAXIME
9.2.6. GENTAMICIN 
10. Community Acquired Pneumonia (CAP) Market – By Drugs provided to different age groups (Market Size -$Million / $Billion)
10.1. Newborns
10.1.1. AMPICILLIN 
10.1.2. GENTAMICIN 
10.2. Children
10.2.1. AMOXICILLIN 
10.2.2. CEFPODOXIME 
10.2.3. AMPICILLIN 
10.2.4. CEFTRIAXONE OR CEFOTAXIME
10.3. Adults
10.3.1. AZITHROMYCIN OR CLARITHROMYCIN
10.3.2. CEFPODOXIME 
10.3.3. AMOXICILLIN 
10.3.4. CEFTRIAXONE OR CEFOTAXIME
11. Community Acquired Pneumonia (CAP) - By Geography (Market Size -$Million / $Billion)
11.1. Community Acquired Pneumonia (CAP) Market - North America Segment Research
11.2. North America Market Research (Million / $Billion)
11.2.1. Segment type Size and Market Size Analysis 
11.2.2. Revenue and Trends
11.2.3. Application Revenue and Trends by type of Application
11.2.4. Company Revenue and Product Analysis
11.2.5. North America Product type and Application Market Size
11.2.5.1. U.S.
11.2.5.2. Canada 
11.2.5.3. Mexico 
11.2.5.4. Rest of North America
11.3. Community Acquired Pneumonia (CAP) - South America Segment Research
11.4. South America Market Research (Market Size -$Million / $Billion)
11.4.1. Segment type Size and Market Size Analysis 
11.4.2. Revenue and Trends
11.4.3. Application Revenue and Trends by type of Application
11.4.4. Company Revenue and Product Analysis
11.4.5. South America Product type and Application Market Size
11.4.5.1. Brazil  
11.4.5.2. Venezuela
11.4.5.3. Argentina
11.4.5.4. Ecuador
11.4.5.5. Peru
11.4.5.6. Colombia 
11.4.5.7. Costa Rica
11.4.5.8. Rest of South America
11.5. Community Acquired Pneumonia (CAP) - Europe Segment Research
11.6. Europe Market Research (Market Size -$Million / $Billion)
11.6.1. Segment type Size and Market Size Analysis 
11.6.2. Revenue and Trends
11.6.3. Application Revenue and Trends by type of Application
11.6.4. Company Revenue and Product Analysis
11.6.5. Europe Segment Product type and Application Market Size
11.6.5.1. U.K  
11.6.5.2. Germany 
11.6.5.3. Italy 
11.6.5.4. France
11.6.5.5. Netherlands
11.6.5.6. Belgium
11.6.5.7. Spain
11.6.5.8. Denmark
11.6.5.9. Rest of Europe
11.7. Community Acquired Pneumonia (CAP) – APAC Segment Research
11.8. APAC Market Research (Market Size -$Million / $Billion)
11.8.1. Segment type Size and Market Size Analysis 
11.8.2. Revenue and Trends
11.8.3. Application Revenue and Trends by type of Application
11.8.4. Company Revenue and Product Analysis
11.8.5. APAC Segment – Product type and Application Market Size
11.8.5.1. China 
11.8.5.2. Australia
11.8.5.3. Japan 
11.8.5.4. South Korea
11.8.5.5. India
11.8.5.6. Taiwan
11.8.5.7. Malaysia
12. Community Acquired Pneumonia (CAP) Market - Entropy
12.1. New product launches
12.2. M&A's, collaborations, JVs and partnerships
13. Community Acquired Pneumonia (CAP) Market – Industry / Segment Competition landscape
13.1. Market Share Analysis
13.1.1. Market Share by Country- Top companies
13.1.2. Market Share by Region- Top 10 companies
13.1.3. Market Share by type of Application – Top 10 companies
13.1.4. Market Share by type of Product / Product category- Top 10 companies
13.1.5. Market Share at global level- Top 10 companies
13.1.6. Best Practises for companies
14. Community Acquired Pneumonia (CAP) Market – Key Company List by Country
15. Community Acquired Pneumonia (CAP) Market Company Analysis
15.1. Market Share, Company Revenue, Products, M&A, Developments
15.2. Pfizer
15.3. Astrazeneca Plc.
15.4. Bioaegis Therapeutics, Inc
15.5. Biotest AG
15.6. C10 Pharma AS
15.7. Kyorin Pharmaceutical Co., Ltd
15.8. Melinta Therapeutics, Inc
15.9. Merck & Co., Inc.
15.10. NABRIVA THERAPEUTICS AG
15.11. Paratek Pharmaceuticals, Inc 
15.12. Company 11
15.13. Company 12
15.14. Company 13 and more
"*Financials would be provided on a best efforts basis for private companies"
16. Community Acquired Pneumonia (CAP) Market - Appendix
16.1. Abbreviations
16.2. Sources
17. Community Acquired Pneumonia (CAP) Market - Methodology
17.1. Research Methodology
17.1.1. Company Expert Interviews
17.1.2. Industry Databases
17.1.3. Associations
17.1.4. Company News
17.1.5. Company Annual Reports
17.1.6. Application Trends
17.1.7. New Products and Product database
17.1.8. Company Transcripts
17.1.9. R&D Trends
17.1.10. Key Opinion Leaders Interviews
17.1.11. Supply and Demand Trends
Please select Licence
Single User Licence:
US $5250
Corporate User Licence:
US $7250
Related Reports
0px;">Scroll